DrugPatentWatch Database Preview
Details for Patent: 8,338,486
Which drugs does patent 8,338,486 protect, and when does it expire?
Patent 8,338,486 protects NAMZARIC and is included in one NDA.
This patent has fifty-eight patent family members in eighteen countries.
Summary for Patent: 8,338,486
Title: | Methods for the treatment of CNS-related conditions |
Abstract: | The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. |
Inventor(s): | Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV) |
Assignee: | Adamas Pharmaceuticals, Inc. (Emeryville, CA) |
Application Number: | 13/536,763 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,338,486 |
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 8,338,486
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan Sales Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-003 | Jul 18, 2016 | RX | Yes | No | Start Trial | Start Trial | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | Start Trial | ||||
Allergan Sales Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-001 | Dec 23, 2014 | RX | Yes | No | Start Trial | Start Trial | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | Start Trial | ||||
Allergan Sales Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-004 | Jul 18, 2016 | RX | Yes | No | Start Trial | Start Trial | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | Start Trial | ||||
Allergan Sales Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-002 | Dec 23, 2014 | RX | Yes | Yes | Start Trial | Start Trial | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,338,486
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 481096 | Start Trial | |||
Australia | 2005209310 | Start Trial | |||
Australia | 2005215767 | Start Trial | |||
Australia | 2005215775 | Start Trial | |||
Australia | 2005309601 | Start Trial | |||
Australia | 2006244297 | Start Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |